Abstract
Thyroid cancer occurs three times more frequently in females than in males, and in females the incidence decreases after menopause. This gender difference suggests that the growth and progression of thyroid cancer may be influenced by female sex hormones, particularly estrogens. Experimental data have clearly demonstrated that estrogens can influence cancer cell growth. The action of estrogens on target sites is mediated through related but distinct estrogen receptors, designated estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), both of which are known to be expressed in thyroid cancer cells. The proliferation of thyroid cancer cells is promoted by an ERα agonist, whereas the proliferation is reduced by the enhanced expression of ERβ or by an ERβ agonist. When ERβ is down-regulated, the proliferation of thyroid cells is significantly increased. Studies have shown that the expression of ERα in thyroid cancer cells is increased while the expression of ERβ is either very low or absent. In conclusion, it appears that estrogens have opposite effects on the growth of thyroid cancer cells, depending on the balance between ERα and ERβ in the cells. The modulation of ERα and ERβ and the intervention of their pathways may open up new potential targets for the treatment of thyroid cancer.
Keywords: Estrogen, estrogen receptors, thyroid, cancer, proliferation, apoptosis
Current Cancer Drug Targets
Title: Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Volume: 8 Issue: 5
Author(s): George G. Chen, Alexander C. Vlantis, Qiang Zeng and C. Andrew van Hasselt
Affiliation:
Keywords: Estrogen, estrogen receptors, thyroid, cancer, proliferation, apoptosis
Abstract: Thyroid cancer occurs three times more frequently in females than in males, and in females the incidence decreases after menopause. This gender difference suggests that the growth and progression of thyroid cancer may be influenced by female sex hormones, particularly estrogens. Experimental data have clearly demonstrated that estrogens can influence cancer cell growth. The action of estrogens on target sites is mediated through related but distinct estrogen receptors, designated estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), both of which are known to be expressed in thyroid cancer cells. The proliferation of thyroid cancer cells is promoted by an ERα agonist, whereas the proliferation is reduced by the enhanced expression of ERβ or by an ERβ agonist. When ERβ is down-regulated, the proliferation of thyroid cells is significantly increased. Studies have shown that the expression of ERα in thyroid cancer cells is increased while the expression of ERβ is either very low or absent. In conclusion, it appears that estrogens have opposite effects on the growth of thyroid cancer cells, depending on the balance between ERα and ERβ in the cells. The modulation of ERα and ERβ and the intervention of their pathways may open up new potential targets for the treatment of thyroid cancer.
Export Options
About this article
Cite this article as:
Chen G. George, Vlantis C. Alexander, Zeng Qiang and van Hasselt Andrew C., Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer, Current Cancer Drug Targets 2008; 8 (5) . https://dx.doi.org/10.2174/156800908785133150
DOI https://dx.doi.org/10.2174/156800908785133150 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?
Current Cancer Therapy Reviews Recent Trend for EGFR-Based and ALK-Based Targets: A Patent Analysis
Recent Patents on Anti-Cancer Drug Discovery Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Plasticity of Neuroendocrine-Immune Interactions During Ontogeny: Role of Perinatal Programming in Pathogenesis of Inflammation and Stress- Related Diseases in Adults
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets The Ca2+-Activated K+ Channel of Intermediate Conductance:A Molecular Target for Novel Treatments?
Current Drug Targets Kinase Inhibitor Conjugates
Current Pharmaceutical Design A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases
Recent Patents on Cardiovascular Drug Discovery Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Genetic Polymorphism of miR-218-2 (rs11134527) in Cervical Cancer: A Case-Control Study on the Bangladeshi Women
MicroRNA FAK and p53 Protein Interactions
Anti-Cancer Agents in Medicinal Chemistry Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Anorexia Nervosa and the Use of Total Parenteral Nutrition Refeeding
Current Nutrition & Food Science Anti-cancer Immunotoxins, Challenges, and Approaches
Current Pharmaceutical Design A Simple and Reliable Approach for Assessing Anticancer Activity In Vitro
Current Medicinal Chemistry Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Hydroxamic Acids, Recent Breakthroughs in Stereoselective Synthesis and Biological Evaluations
Current Organic Synthesis Genetic Polymorphism of Organic Anion and Cation Transporters: Pharmacokinetic and Pharmacodynamic Consequences in Pharmacotherapy
Current Pharmacogenomics Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents